Bronchitis Market Research Report - Forecast to 2030

Bronchitis Market Information: By Type (Acute Bronchitis, Chronic Bronchitis), Diagnosis (Chest X-Ray, Sputum Tests, Pulmonary Function Test), Devices (Drugs, Oxygen Therapy), End-User (Hospitals, Clinics, Pharmacies)- Global Forecast Till 2030

ID: MRFR/Pharma/4303-HCR | September 2022 | Region: Global | 110 Pages         

Bronchitis Market Speak to Analyst Request a Free Sample

Synopsis of the Bronchitis Market


Bronchitis is nothing but the inflammation of the lining of bronchial tubes of the lungs. It is of two types, namely, acute and chronic bronchitis. Acute bronchitis, also known as a chest cold, is found to be very common and develops from a cold or other respiratory infection. On the other hand, chronic bronchitis is a severe condition which is characterized by constant irritation or inflammation of the lining of bronchial tubes. It is included in the Chronic Obstructive Pulmonary Disease (COPD). Shortness of breath, cough, slight fever and chills, production of mucus, fatigue, and chest discomfort are major symptoms of bronchitis. It can be diagnosed through various tests such as chest X-ray, sputum tests, and pulmonary function test.


The bronchitis market is mainly driven by the increasing prevalence of lung diseases such as bronchitis, asthma, COPD, availability of drugs for the treatment, and drugs. Additionally, increasing number of diagnostic services for various chronic diseases and the use of technologically advanced devices for diagnosis also drive the growth of the market. Other factors supporting the market growth are an addiction to smoking and changing lifestyle. However, fierce competition among the existing market players restrains the growth of the market.


The bronchitis market is expected to grow at a CAGR of 7.10% during the forecast period.


Segments  


The bronchitis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the bronchitis market is segmented into acute bronchitis and chronic bronchitis.


On the basis of diagnosis, the bronchitis market is segmented into chest X-ray, sputum tests, and pulmonary function tests.


On the basis of treatment, the bronchitis market is segmented into drugs and oxygen therapy. Drugs is further segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics.


On the basis of end-user, the bronchitis market is segmented into hospitals, clinics, pharmacies, research institutes, and others.


FIGURE 1: Global Bronchitis Market, by Region, 2016 (%)


 Bronchitis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology Bronchitis Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Bronchitis Market                  


The American bronchitis market is segmented into two regions, namely, North America and South America. North America is the largest market with huge patient pool, growing awareness about bronchitis treatment among the people and presence of major players in the market. South America is expected to be the fastest growing market with the increasing demand for diagnostic services.


In Europe, the bronchitis market is driven by the increasing focus on research and development activities for the treatment of chronic bronchitis. Germany and the U.K. occupy a first and second position in the European market which is driven by the increasing demand for diagnostic services for respiratory diseases and the emergence of new players in the market manufacturing various classes of drugs in the market.


The bronchitis market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing environmental population, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases among the adults. Additionally, growth in the number of people addicted to smoking and increasing number of patients with COPD fuel the market in this region.


The Middle Eastern and African market for bronchitis exhibits a steady rise with the growing awareness about causes, diagnosis, and treatment of chronic diseases. The demand for primary care services including diagnostic services for respiratory diseases fuels the market growth in Africa.


Key Players in the Bronchitis Market    


Some of the key players in this bronchitis market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   7.10% (2020-2030)
  Base Year   2020
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of lung diseases
  • Availability of drugs for the treatment, and drugs


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Bronchitis is an inflammation of the bronchial tubes in the lungs. It can be acute or chronic.

    Bronchitis Market is expected to exhibit a strong 7.10% CAGR over the forecast period till 2030.

    The increasing prevalence of lung diseases is the major driver for the Bronchitis Market.

    The Americas hold the dominant share in the Global Bronchitis Market.

    Leading players in the Bronchitis Market include GSK, Boehringer Ingelheim, and Sanofi, among others.